Home Newsfeeds ProMIS Neurosciences Q3 EPS $(0.85) Down From $(0.20) YoY

ProMIS Neurosciences Q3 EPS $(0.85) Down From $(0.20) YoY

ProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(0.85) per share. This is a 325 percent decrease over losses of $(0.20) per share from the same period last year.

byBenzinga Newsdesk

November 14, 2022

1 minute read

ProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(0.85) per share. This is a 325 percent decrease over losses of $(0.20) per share from the same period last year.

HC Wainwright & Co. Maintains Buy on IGM Biosciences, Lowers Price Target to $45

By Benzinga Newsdesk

November 7, 7:27 AM

HC Wainwright & Co. analyst Robert Burns maintains IGM Biosciences (NASDAQ:IGMS) with a Buy and lowers the price target from $58 to $45.

IGMS

Bill Announces The Promotion Of John Rettig To Company President

By Benzinga Newsdesk

November 2, 5:13 PM

New Role Reflects Momentum and Scale of BILLBILL (NYSE:BILL), a leading financial operations platform for small and midsize businesses (SMBs), today announced BILL Chief Financial Officer (CFO) John Rettig has been

BILL

General
News

Moderna CEO Highlights Promising Cancer Vaccine Data: ‘Think About The Number Of Lives That Can Be Impacted’

By Erica Kollmann

December 14, 5:03 PM

Moderna, Inc. (NASDAQ: MRNA) CEO Stéphane Bancel appeared on CNBC's "Squawk Box" Thursday to discuss the company's promising new cancer vaccine developed in

MRK